Catenion

Which biopharma companies had the highest R&D productivity and growth in the past year? What were the key drivers behind it? What are the biggest trends propelling the industry at the moment?   Catenion Senior Partner Dr. Markus Thunecke summarizes the main insights of our annual R&D productivity report in this new video. A must-watch! 🔍 Key Highlights: ● Top 30 R&D productivity increased – growing gap between top 10 and rest ● Novo Nordisk tops ranking again – the gift that keeps on giving ● Vertex Pharmaceuticals sits comfortably at number two in R&D productivity ● Will obesity success propel Eli Lilly and Company to $1,000 bn market cap? ● Moderna and BioNTech SE – two diverging strategies ● Enhertu and Daiichi Sankyo US's ADC platform keep winning ● Jazz Pharmaceuticals – rookie in the top 10 ● ...and much more 📈 Read the full report here: https://lnkd.in/d6Cwm4fa Paper authors: Dr. Markus Thunecke, Dr. Erika Kuchen, Dr. Alexander Wallroth Published by In Vivo Citeline, Citeline Commercial   #Catenion #BiophamaConsulting #RnDProductivity #BiopharmaInnovation

🧠 Meet Catenion at 𝗕𝗶𝗼 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟱! 🧠 CNS drug development presents some of the toughest challenges in biopharma, and we’re excited to join the discussion at 𝗕𝗶𝗼 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟱 in Amsterdam (Feb 25-27). Connect with our colleague Dr. Mayur Vadhvani to explore the latest breakthroughs and R&D strategies! 📍 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺 | 𝗙𝗲𝗯 𝟮𝟱-𝟮𝟳 🔗 𝗘𝘃𝗲𝗻𝘁 𝗱𝗲𝘁𝗮𝗶𝗹𝘀: https://lnkd.in/ek7dRNvy #CNS #Neuroscience #Biopharma #DrugDevelopment #Catenion #BioNeuroscience2025

📢 Catenion Consultant Dr. Daniel Bauer will be in Santa Fe, NM, next week for the Keystone Symposia meeting on 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻. 💡 Reach out to Daniel or email us at info@catenion.com to schedule a discussion on the latest developments in the TPD space! #DrugDiscovery #TargetedProteinDegradation #TPD #KSProxDrugs25

🎉 Congratulations to Catenion consultant Lea Jopp-Saile and her team for winning the 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁 𝗔𝘄𝗮𝗿𝗱 at the Owkin & Servier AI Hackathon for Glioblastoma Research earlier this week! We are excited to see AI-driven innovation tackling complex healthcare challenges 👏 #AI #Glioblastoma #Innovation #ClinicalImpact #PharmaConsulting

💡 Next week, Catenion data scientist Lea Jopp-Saile is heading to Paris to participate in the Owkin & Servier 𝗔𝗜 𝗛𝗮𝗰𝗸𝗮𝘁𝗵𝗼𝗻 𝗳𝗼𝗿 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵. This initiative represents an important opportunity to advance glioblastoma research by combining AI and patient-derived single-cell and spatial omics data in a collaborative, interdisciplinary setting. 🚀 We wish Lea and all participants great success in tackling this important challenge! At Catenion, we stay at the forefront of AI advancements through our dedicated data unit, ensuring our biopharma clients benefit from the latest innovations in data science and AI-driven insights. Contact us at info@catenion.com to learn how we use AI to help your team tackle large-scale and complex datasets.   #Hackathon #AI #Glioblastoma #Innovation #Collaboration #PharmaConsulting #LifeScienceConsulting

🌍 Join Catenion Senior Partner Matthias Krings at the Hevolution Foundation's Global Healthspan Summit next week to discuss healthy aging, an area attracting increased attention in global healthcare. 📅 Drop a line to connect or get in touch via info@catenion.com to schedule a meeting. #GSH2025 #Healthspan #Aging #PharmaConsulting #LifeScienceConsulting

🚨 Meet Catenion's Senior Partner Matthias Krings at Arab Health Exhibition for insights into the ever-evolving biopharma industry! 📩 Interested? Leave us a message here on LinkedIn or email us at info@catenion.com to schedule a meeting. #ArabHealth #PharmaConsulting #LifeScienceConsulting

🛣️𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗿𝗲 𝗮𝘁 𝗮 𝗰𝗿𝗼𝘀𝘀𝗿𝗼𝗮𝗱𝘀 – 𝘸𝘩𝘦𝘳𝘦 𝘸𝘰𝘶𝘭𝘥 𝘺𝘰𝘶 𝘪𝘯𝘷𝘦𝘴𝘵 𝘺𝘰𝘶𝘳 𝘮𝘰𝘯𝘦𝘺? (𝗽𝗮𝗿𝘁 𝟮) - 𝗖𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀, 𝗔𝗗𝗖𝘀, 𝗥𝗟𝗧𝘀 𝗮𝗿𝗲 𝗴𝗮𝗶𝗻𝗶𝗻𝗴 𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻: While non-niche precision and immuno-oncology show signs of saturation, newer areas like cell therapy, radioligand therapy, and ADCs have gained traction.  - 𝗠𝘂𝗹𝘁𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝘀 𝗮𝗻𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗮𝗿𝗲 𝗴𝗮𝗶𝗻𝗶𝗻𝗴 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺: Cancer vaccines and multispecifics are benefiting from strong data and renewed interest, yet their history of volatility raises questions around sustainability.  - 𝗧𝗣𝗗 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻 𝗮𝘀 𝗮 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗲𝗿: Targeted protein degradation is emerging as a potential game-changer, but its success in tackling difficult targets remains to be seen.  - 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗹𝗲𝘁𝗵𝗮𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗻𝗶𝗰𝗵 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗿𝗲 𝗼𝘂𝘁 𝗼𝗳 𝗳𝗮𝘃𝗼𝗿:  Meanwhile, approaches like synthetic lethality and niche precision are fading, leaving the industry to reconsider which strategies will truly drive future breakthroughs 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘆𝗼𝘂 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗶𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗳𝗼𝗿 𝟮𝟬𝟮𝟱? ❓ 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿? Reach out to schedule a 1-on-1 discussion with us at info@catenion.com With over 20 years of experience, Catenion partners with investors, biotech companies, and pharmaceutical leaders to guide R&D and strategic decisions. 🔔 For more insights on biopharma trends, follow us and explore our hashtag #CatenionInsights  📝 Discover more on our website: https://lnkd.in/eMFmUWbs  Credits: Bea Kaufmann #Oncology #JPM #2025 #JPM2025 #RnDinPharma #DrugDiscovery #MarketDynamics #TrendsinPharma #WNinOncology

🤔𝗛𝗼𝘄 𝘄𝗶𝗹𝗹 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘀𝘁𝗮𝗿𝘁 𝗶𝗻𝘁𝗼 𝟮𝟬𝟮𝟱 – 𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗖𝗮𝘁𝗲𝗻𝗶𝗼𝗻 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗽𝗿𝗲-𝗝𝗣𝗠 (𝗽𝗮𝗿𝘁 𝟭) 📈𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆  ● 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗿𝘂𝗴𝘀 𝗮𝗿𝗲 𝗼𝗳 𝗵𝗶𝗴𝗵 𝘃𝗮𝗹𝘂𝗲 𝗰𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗶𝗼𝗻 With only a fraction of marketed oncology drugs accounting for the majority of total oncology sales, what does this concentration of value mean for the future of the market?  ● 𝗠𝗼𝘀𝘁 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗼𝗻𝗹𝘆 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝗺𝗼𝗱𝗲𝘀𝘁 𝗺𝗲𝗱𝗶𝗮𝗻 𝘀𝗮𝗹𝗲𝘀 Why do so many therapies achieve modest peak sales, despite the immense competition and investment in oncology? With a 50% chance of staying below ~$400 million in peak revenue, are we overestimating the potential of many treatments?  ●𝗪𝗵𝗶𝗹𝗲 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗵𝗮𝘃𝗲 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗿𝗮𝘁𝗲𝘀, 𝘄𝗵𝘆 𝗮𝗿𝗲 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝘀 𝘀𝘁𝗶𝗹𝗹 𝗹𝗶𝗺𝗶𝘁𝗲𝗱?  In a market as competitive and commercially attractive as oncology, what will it take to overcome these challenges and unlock the next breakthrough? 📊𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 Oncology remains the most competitive space in drug development.  ● 𝗪𝗵𝗮𝘁 𝗱𝗿𝗶𝘃𝗲𝘀 𝘁𝗵𝗲 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗶𝗻𝘁𝗲𝗻𝘀𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗶𝘀 𝘀𝗽𝗮𝗰𝗲, despite the significant challenges?  ● 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘁𝗵𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗼𝘃𝗲𝗿𝗰𝗼𝗺𝗲 𝘁𝗵𝗲 𝗵𝘂𝗿𝗱𝗹𝗲𝘀 to unlock breakthroughs in such a dynamic field? ● 𝗜𝘀 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝘄𝗼𝗿𝘁𝗵 𝘁𝗵𝗲 𝗳𝗶𝗲𝗿𝗰𝗲 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗵𝗶𝗴𝗵 𝗿𝗶𝘀𝗸𝘀 𝗶𝗻𝘃𝗼𝗹𝘃𝗲𝗱?  So, where is the field heading? ✨𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗳𝗼𝗿 𝗽𝗮𝗿𝘁 𝟮 𝗰𝗼𝗺𝗶𝗻𝗴 𝗹𝗮𝘁𝗲𝗿 𝘁𝗵𝗶𝘀 𝘄𝗲𝗲𝗸✨ ❓ 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿? Reach out to schedule a 1-on-1 discussion with us at info@catenion.com With over 20 years of experience, Catenion partners with investors, biotech companies, and pharmaceutical leaders to guide R&D and strategic decisions. 🔔 For more insights on biopharma trends, follow us and explore our hashtag #CatenionInsights  📝 Discover more on our website: https://lnkd.in/eMFmUWbs  Credits: Bea Kaufmann #Oncology #JPM #2025 #RnDinPharma #DrugDiscovery #MarketDynamics #TrendsinPharma

🔍 𝗤𝘂𝗮𝗻𝘁𝘂𝗺 𝗖𝗼𝗺𝗽𝘂𝘁𝗶𝗻𝗴 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 𝗥&𝗗: 𝗪𝗵𝗲𝗿𝗲 𝗔𝗿𝗲 𝗪𝗲 𝗡𝗼𝘄, 𝗮𝗻𝗱 𝗪𝗵𝗲𝗿𝗲 𝗔𝗿𝗲 𝗪𝗲 𝗛𝗲𝗮𝗱𝗲𝗱? Quantum computing leverages the unique properties of quantum physics to process complex data exponentially faster than classical computers, allowing heretofore infeasible computations. It holds immense promise for revolutionizing pharmaceutical R&D—but what does the reality look like today? 🧩 In this visual breakdown, we explore the hype cycle of quantum computing in pharma R&D, outlining the potential future development in the field. 🧪 𝗧𝗵𝗲 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 Quantum systems could simulate molecular interactions at an atomic level, analyze massive datasets to identify biomarkers, and optimize supply chains. Adoption is limited but growing, with initial partnerships formed to explore potential use cases, mostly focused on drug design. ⚠️ 𝗛𝗮𝗿𝗱𝘄𝗮𝗿𝗲 𝗮𝗻𝗱 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 To succeed and gain industry adoption, quantum computing needs to overcome hardware limitations and the insufficient number of qubits leading to noisy, unreliable results as well as develop compatible algorithms and grow specialized teams. Moreover, classical computing continues to advance, often delivering practical results faster and more reliably. Nevertheless, Google’s recent chip breakthrough and IBM’s plan to build an even larger quantum computer in 2025 are just some of the recent advances in the field. 🧬 𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 If the true bottleneck in drug development lies in understanding biology rather than computation, then faster technology may only enable us to move in the wrong direction more quickly. Combining breakthroughs in technology with a better understanding of underlying disease mechanisms will be the key to unlocking the next generation of life-saving therapies. 📊 The future of quantum in pharma R&D teeters between breakthrough innovation and practical hurdles. What’s your take? Will quantum revolutionize the biopharma industry? 🚀 ❓ 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿? Reach out to schedule a 1-on-1 discussion with us at info@catenion.com With over 20 years of experience, Catenion partners with investors, biotech companies, and pharmaceutical leaders to guide R&D and strategic decisions. 🔔 For more insights on biopharma trends, follow us and explore our #CatenionInsights  📝 Discover more on our website: https://lnkd.in/eMFmUWbs  Credits: Veronika Shamova, Pascal Stehling, Erika Kuchen #QuantumComputing #PharmaRnD #Innovation #CatenionInsights #DrugDiscovery #TechTrends #AI